HOLX
HealthcareHologic, Inc.
$74.75
+$0.19 (+0.25%)
Jan 5, 2026
Price History (1Y)
Analysis
Hologic, Inc. operates in the healthcare sector, specifically within the medical instruments and supplies industry. The company has a significant scale, with a market capitalization of $16.67 billion, annual revenues of $4.10 billion, and over 7,070 employees. The company's financial health is characterized by moderate profitability margins, with gross margin at 60.8%, operating margin at 32.7%, and profit margin at 13.8%. Hologic also generates substantial returns on equity (11.1%) and assets (7.3%), while maintaining a debt-to-equity ratio of 52.04. Notably, the company has a cash balance of $2.21 billion, which is offset by a debt level of $2.63 billion. Hologic's valuation metrics include a price-to-earnings ratio of 29.90 (TTM) and 14.96 (forward), as well as a price-to-book ratio of 3.30. The company has experienced revenue growth of 6.2% year-over-year, with earnings growth at 11.1%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Hologic, Inc.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $16.67B
- P/E Ratio
- 29.90
- 52-Week High
- $75.34
- 52-Week Low
- $51.90
- Avg Volume
- 3.47M
- Beta
- 0.70
Company Info
- Industry
- Medical Instruments & Supplies
- Exchange
- NMS
- Country
- United States
- Employees
- 7,070